Braidwell LP Acquires New Stake in Avalyn Pharma Inc. $AVLN

Braidwell LP acquired a new position in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 801,395 shares of the company’s stock, valued at approximately $26,382,000.

Separately, Montanova Capital LLC purchased a new position in Avalyn Pharma in the 2nd quarter valued at about $82,402,000.

Avalyn Pharma Trading Up 0.9%

NASDAQ AVLN opened at $35.58 on Thursday. The stock’s 50-day simple moving average is $32.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. Avalyn Pharma Inc. has a twelve month low of $24.15 and a twelve month high of $40.17. The stock has a market capitalization of $1.58 billion and a P/E ratio of -1.56.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. Equities analysts predict that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AVLN. Evercore started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price target for the company. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Guggenheim began coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.